(Press-News.org) Tuberculosis is old—ancient even. The infectious bacterial disease that plagued Old Testament Israelites and took down pharaohs was eventually stunted by vaccinations, antibiotics, and public health measures like isolation, but it hasn’t been cured yet. More than a million people around the world still die from TB every year.
Now, a Boston University-led research team has found a way to tweak immune cells to better fight the disease and—with the right backing and funding—they say it could be ready for clinical trials as soon as next year. In a study published in Science Advances, the researchers identified the genetic signatures of TB-susceptible and TB-resistant white blood cells, called macrophages, and then tested the ability of different compounds to transform vulnerable cells into more resilient ones.
“The TB vaccine is not really 100 percent efficient and antibiotic resistance is becoming more prevalent,” says Igor Kramnik, the study’s corresponding author and a BU Chobanian & Avedisian School of Medicine associate professor of medicine. His team’s approach could add another weapon to the arsenal that’s fighting TB: a host-directed therapy, a way of helping the body better control infection and reduce disease-related inflammation. “It’s a way of treating the host, the patient, rather than focusing on the pathogen.” The project mixed lab-based studies at BU’s National Emerging Infectious Diseases Laboratories (NEIDL) with a big data audit of potential compounds by scientists at University College Dublin, Ireland.
“Tuberculosis, as one of my colleagues used to say, has studied us much longer than we have studied it,” says Kramnik, who’s also a NEIDL investigator. “It’s a serious and complex disease and our standard interventions are only partially efficient—none of them are sufficient to eradicate the disease.”
But the latest work could help change that, according to Shivraj M. Yabaji, a NEIDL postdoctoral researcher.
“We hope that our research will contribute to the development of more effective treatments for TB by better understanding how to fine tune the activation states of immune cells,” says Yabaji, the paper’s lead author. “This could potentially lead to therapies that target host immunity to tuberculosis.”
Weak TB Vaccine, Rising Antimicrobial Resistance
The cause of tuberculosis is a bacteria called Mycobacterium tuberculosis—a tiny rod-shaped germ less than 0.5 micrometers in diameter. Spread by a cough, sneeze, or even just a conversation, it can cause symptoms like fever, weight loss, and chest pain. In 2021—the most recent numbers available—more than 10 million people worldwide fell ill with TB, with the disease typically concentrating its attacks on their lungs.
For 100 years, a vaccine—bacille Calmette-Guérin (BCG)—has been the first line of defense against TB, albeit a somewhat ramshackle one. A recent study from Boston University showed that BCG has limited impact: researchers found it was only about 37 percent effective in children under five years of age and offered no protection for adolescents and adults. And antibiotics, the fallback for those who do become infected, are losing their power. According to the World Health Organization, “drug-resistant tuberculosis is a major contributor to antimicrobial resistance worldwide and continues to be a public health threat;” it reports that around 500,000 people die annually from drug-resistant TB.
Kramnik has been studying TB for 30 years, though he’d initially expected to only spend a few years scrutinizing it before turning his focus to tumor biology.
“I thought that tuberculosis would be a nice stepping stone, but I’m still here, trying to understand it,” he says. “It’s a disease that’s very different from others. Thinking about tuberculosis as a battle between a pathogen and a host isn’t really productive. What we’re probably dealing with is an evolutionarily refined coexistence of a pathogen and a host that eventually leads to incurable disease at its terminal stage.”
A New Treatment to Enhance Natural Defenses Against TB
One of TB’s biggest mysteries is why some people get sick when most others don’t; in particular, why so many patients initially ward off infection, then eventually succumb to it. Kramnik is also interested in why the bacteria is so intent on destroying the lung, which enables its transmission by infectious aerosols. In recent studies, his lab has used experimental mouse models, which mimic what happens to humans when they contract TB, to try to provide some answers.
“It all led us to identify the importance of macrophage cells as major determinants, and regulators and controllers, of local immune response in the lung,” he says, “and a major cell that affects susceptibility in cases of growing infection.”
Macrophages typically have two disease fighting states, says Kramnik: an active one that takes on and eliminates pathogenic intruders, and a regenerative one that helps rebuild tissue after infection. He discovered that in the case of TB, the cells can get stuck in a hyperactive, but ineffective, fight mode: a persistent and damaging inflammatory response that hurts the body, but doesn’t take down the pathogen. In the latest study, Kramnik, Yabaji, and their colleagues used the mouse models to look for ways to shut this response off and help the macrophages work more effectively.
To start, they used RNA sequencing—a method for pinpointing which genes are expressed, or turned on—hoping it would help them zero in on the “genetic signature that differentiates the normal/resistant and aberrant/susceptible activation states,” says Kramnik. Using a test developed in collaboration with study coauthor Alexander A. Gimelbrant, an investigator at the Seattle-based Altius Institute for Biomedical Sciences, the team simultaneously measured the expression of 46 different genes that represented this signature. “This allowed us to look at gene expression patterns rather than individual genes to characterize the cell states and their changes in response to treatments.” They then tested a range of drugs to see if any would perturb, or change, the expression of the genes.
Some molecules worked better than others, but no single one could shift a macrophage from a TB-vulnerable to a TB-resistant state. To uncover a potential combination that would work in synergy, the lab-based team sent all of their data to researchers at University College Dublin, Ireland, who had developed a machine learning algorithm they could use to predict whether particular combinations of drugs would be more effective. “We then went back to the bench and tested those predictions,” says Kramnik.
They found two molecules that have shown promise as cancer treatments—Rocaglamide A (RocA) and a c-Jun N-terminal kinase (JNK) inhibitor—formed an especially good partnership. Together, they helped hinder cell signals related to inflammation and stress, while also boosting the pathways that carry stress resistance signals. “They would be good candidates for clinical trials, so it could change the medical treatment of tuberculosis,” says Kramnik.
The researchers also discovered that using the two together allowed them to dial back on the effective dose of RocA, which can be potentially toxic at higher levels. Kramnik says their results show how to increase “therapeutic efficacy at lower drug doses and decrease toxic side effects. This is particularly important for chronic diseases that require long course treatments, such as tuberculosis.”
Although the team is ready to move the research forward, bringing any therapy to trial would require fresh backing, whether from a pharmaceutical company or other institution. “We will be in position,” says Kramnik, “to partner with people who can bring it to the clinic. This is our goal.”
Researchers find potential way to tweak immune system to help it fight tuberculosis
TB is the world’s second deadliest infectious disease behind COVID-19. A new BU-led study shows how to turn TB-susceptible immune cells into TB-resistant ones
ELSE PRESS RELEASES FROM THIS DATE:
Researchers discover disease-causing stem cells in lungs of cystic fibrosis patients
Two nationally recognized experts in cloning and stem cell science from the University of Houston, Wa Xian and Frank McKeon, are reporting that five lung stem cell variants dominate the lungs of patients with advanced cystic fibrosis (CF), and that these variants drive key aspects of CF pathology including inflammation, fibrosis and mucin secretion. Cystic fibrosis is an inherited and progressive disease that causes long-lasting lung infections and limits the ability to breathe. It is caused by a defect in a gene called the cystic fibrosis transmembrane conductance regulator ...
Combating distrust online: New GW study explains why current messaging efforts may not be effective
WASHINGTON (September 27, 2023) - New research led by the George Washington University finds that current mitigation efforts to combat distrust online may not be effective because organizations and governments tackling distrust are only targeting one topic and only one geographical scale. The study shows that online distrust has become a ‘glocal’ phenomenon, meaning that it is spreading with different topics lumped together and mixing both local and global interests. “The key takeaway here is that distrust ...
When needs compete, love trumps thirst
ITHACA, N.Y. – While many studies have investigated the neuroscience behind how an animal learns to achieve a goal, such as obtaining water when thirsty, none have understood how animals choose between several competing needs – until now. A Cornell University-led study, published Sept. 27 in the journal Nature, used advanced techniques developed by researchers to track the brain’s dopamine reward system and found – for the first time – this system flexibly retunes toward the most important goal when faced with multiple competing needs. In the study, when a lonely and thirsty male zebra finch encountered a female, his thirst waned and ...
NIH awards merit grant for nanofiber research targeting metastatic lung tumors
Dr. Vanessa Bellat, an assistant professor of chemistry in radiology and an affiliate of the Molecular Imaging Innovations Institute (MI3) at Weill Cornell Medicine, has been awarded a $2 million, four-year R37 MERIT grant from the National Cancer Institute, part of the National Institutes of Health. She will be developing a new therapeutic approach using nanofibers that selectively deliver drugs to the lungs to treat metastatic tumors and testing it in preclinical models. These fibers are made from peptide chains (building blocks that make up proteins) and have a unique 2-dimensional single ...
UTA research: Wildlife loss five times slower in protected areas
Protecting large areas of land from human activity can help stem the tide of biodiversity loss, especially for vertebrates like amphibians, reptiles, mammals and birds, according to a new study in Nature. In particular, vertebrate population declines were five times slower in conservation areas compared to animals living in areas not protected from development or conversion to agricultural use. “Protected areas take us from a situation in which biodiversity is ebbing away to one where populations are at least close to stable,” said Luke Frishkoff, coauthor of the study and assistant professor of biology at The University of Texas at Arlington. ...
Milestone for novel atomic clock
An international research team has taken a decisive step toward a new generation of atomic clocks. At the European XFEL X-ray laser, the researchers have created a much more precise pulse generator based on the element scandium, which enables an accuracy of one second in 300 billion years – that is about a thousand times more precise than the current standard atomic clock based on caesium. The team presents its success in the journal Nature. Atomic clocks are currently the world’s ...
NSF backs Rice processor design, chip security research
HOUSTON – (Sept. 27, 2023) Rice University computer scientists have won two grants from the National Science Foundation to explore new information processing technologies and applications that combine seamlessly co-designed hardware and software to allow for more effective and efficient data stream analysis using pattern matching. Initiated by a Rice seed grant, the projects address the limitations of current computing infrastructure’s ability to process complex, unstructured data streams. A $1.2 million award will ...
St. Jude Children’s Research Hospital unveils the Domino’s Village
MEMPHIS, Tenn., Sept. 27, 2023 – St. Jude Children’s Research Hospital® and Domino’s®, the largest pizza company in the world, today unveiled The Domino’s Village, a multi-million dollar housing facility for patients and their families. The six-story building that provides more than 307,000 square feet of residential and recreational space was funded by Domino’s as part of a 10-year, historic $100 million commitment to St. ...
U of M Medical School professor receives $3.5 million to develop Tanzanian reproductive health curriculum for those with disabilities
MINNEAPOLIS/ST. PAUL (09/27/2023) — Kristen Mark, PhD, with the University of Minnesota Medical School, received a $3.5 million grant from the National Institutes of Health to enhance the quality of life for individuals with disabilities in Tanzania through a new project. The research team will train future healthcare providers like nurses, doctors and midwives with the skills and confidence to offer comprehensive sexual and reproductive healthcare services for people with disabilities. “Through doing this research, we will improve the lives of people with disabilities in Tanzania and build in-country capacity ...
How liver cells become scarring, and worse
Hepatic fibrosis occurs when scar tissue replaces damaged cells in the liver. Over time, accumulating scarring distorts the liver, interferes with its blood supply and may progressively lead to worsening consequences, from cirrhosis to liver failure to liver cancer. In advanced cases, the only treatment is an organ transplant. In a new paper, published online in the journal Cellular and Molecular Gastroenterology and Hepatology, a team of scientists led by corresponding authors David A. Brenner, ...
LAST 30 PRESS RELEASES:
ASH: Novel combination therapy significantly reduces spleen volume in patients with myelofibrosis
ASH: Novel menin inhibitors show promise for patients with advanced acute myeloid leukemias
ASH: Targeted oral therapy reduced disease burden and improved symptoms for patients with rare blood disorder
New Sylvester cancer study provides insight into underlying gene mutations in myelodysplastic syndromes
First-in-human clinical trial of CAR T cell therapy with new binding mechanism shows promising early responses
Long-term results show combination treatment that skips chemotherapy is effective for older patients with Ph+ ALL
Mindfulness could help women with opioid use disorder better control drug urges
TTUHSC’s ARPA-H membership will spur innovation, improve access for West Texas patients
Global annual finance flows of $7 trillion fueling climate, biodiversity, and land degradation crises
Tracing how the infant brain responds to touch with near-infrared spectroscopy
These are the world's most effective charities
When is an aurora not an aurora?
Advisory panel issues field-defining recommendations for US government investments in particle physics research
Doctors discover many patients at UNC’s Inflammatory Bowel Disease Clinic screen positive for malnutrition
BNL: Advisory panel issues field-defining recommendations for U.S. government investments in particle physics research
International collaboration uses faculty member’s research on ancient Roman migration, seeks to understand Balkan genomic history
USF Health Heart Institute doctors are upbeat about cardiac regeneration
AI-driven breakthroughs in cells study: SFU-UBC collaboration introduces "MCS-detect" for advancements in super-resolution microscopy
Advisory panel issues field-defining recommendations for investments in particle physics research
$3.8 million NIH grant to fund Southwest Center on Resilience for Climate Change and Health
What happens when the brain loses a hub?
Study reveals Zika’s shape-shifting machinery—and a possible vulnerability
RIT leading STEM co-mentoring network
Genetic mutations that promote reproduction tend to shorten human lifespan, study shows
CAMH develops potential new drug treatment for multiple sclerosis
Polyethylene waste could be a thing of the past
A dynamic picture of how we respond to high or low oxygen levels
University of Toronto researchers discover new lipid nanoparticle that shows muscle-specific mRNA delivery, reduces off-target effects.
Evolving insights in blood-based liquid biopsies for prostate cancer interrogation
Finding the most heat-resistant substances ever made[Press-News.org] Researchers find potential way to tweak immune system to help it fight tuberculosis
TB is the world’s second deadliest infectious disease behind COVID-19. A new BU-led study shows how to turn TB-susceptible immune cells into TB-resistant ones